The company's breakthrough potential comes not from collecting raw DNA, but from linking it at an individual level to a rich set of "phenotype" data, including proteomics, metabolomics, and transcriptomics. This deep, multi-layered dataset from novel populations is what unlocks actionable insights for drug discovery.

Moonwalk enhances a commercial large language model by training it on their vast internal datasets of genetic, epigenetic, and siRNA screening results. This transforms the general AI into a specialized expert that can prioritize drug targets and generate unique biological insights, creating a significant competitive advantage.

Allergy and AI Therapeutics uses a proprietary AI application to consolidate and query data from thousands of publications and public databases. This allows their team to rapidly answer critical questions about a potential target's expression on normal versus diseased tissue, significantly speeding up the target selection and validation process.

Xaira's core strategy involves creating massive, proprietary datasets that reveal causal biology. By systematically perturbing every gene in a cell to observe its effects, they generate unique training data for their models, quadrupling the world's supply of such information with a single publication.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

A new 'Tech Bio' model inverts traditional biotech by first building a novel, highly structured database designed for AI analysis. Only after this computational foundation is built do they use it to identify therapeutic targets, creating a data-first moat before any lab work begins.

Instead of traditional methods, Regeneron sequences millions of people to find "superhumans"—those with rare genetic mutations that protect them from diseases. By studying these individuals, they identify high-confidence drug targets that mimic these natural protections, aiming for a higher probability of success in development.

Haya's AI platform is differentiated by its focus on deconvoluting the "dark genome" to identify completely novel, "first-in-biology" targets. This contrasts with AI applications that merely optimize molecules for known biological pathways or targets.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.